Compare Stocks: BCAX, COGT, XENE, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.54B	-0.82	598,424 shs	296,877 shs
COGT Cogent Biosciences	$34.76 -0.5%	$38.50	$11.60 ▼ $43.73	$6.06B	0.31	1.66 million shs	784,078 shs
PTCT PTC Therapeutics	$69.30 -2.9%	$75.80	$56.51 ▼ $90.87	$5.96B	0.55	804,196 shs	673,537 shs
XENE Xenon Pharmaceuticals	$59.75 -1.1%	$63.57	$35.60 ▼ $72.66	$5.84B	0.61	673,746 shs	459,131 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-0.73%	-1.11%	-10.51%	+15.85%	+93.08%
COGT Cogent Biosciences	-0.54%	+0.26%	-17.80%	+12.06%	+165.75%
PTCT PTC Therapeutics	-2.94%	-1.13%	+0.13%	-2.35%	+24.75%
XENE Xenon Pharmaceuticals	-1.08%	-0.40%	-7.08%	+15.50%	+53.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.54B	-0.82	598,424 shs	296,877 shs
COGT Cogent Biosciences	$34.76 -0.5%	$38.50	$11.60 ▼ $43.73	$6.06B	0.31	1.66 million shs	784,078 shs
PTCT PTC Therapeutics	$69.30 -2.9%	$75.80	$56.51 ▼ $90.87	$5.96B	0.55	804,196 shs	673,537 shs
XENE Xenon Pharmaceuticals	$59.75 -1.1%	$63.57	$35.60 ▼ $72.66	$5.84B	0.61	673,746 shs	459,131 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-0.73%	-1.11%	-10.51%	+15.85%	+93.08%
COGT Cogent Biosciences	-0.54%	+0.26%	-17.80%	+12.06%	+165.75%
PTCT PTC Therapeutics	-2.94%	-1.13%	+0.13%	-2.35%	+24.75%
XENE Xenon Pharmaceuticals	-1.08%	-0.40%	-7.08%	+15.50%	+53.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	40.86% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	48.32% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	42.20% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	29.09% Upside

Current Analyst Ratings Breakdown

Latest BCAX, COGT, XENE, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $52.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$2.69 per share	N/A
PTCT PTC Therapeutics	$1.73B	3.34	$8.51 per share	8.14	($1.98) per share	-35.00
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	$12.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	32.54	2.20	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest BCAX, COGT, XENE, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
COGT Cogent Biosciences	0.48	13.57	13.57
PTCT PTC Therapeutics	N/A	3.39	3.28
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
COGT Cogent Biosciences	N/A
PTCT PTC Therapeutics	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
COGT Cogent Biosciences	6.59%
PTCT PTC Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
COGT Cogent Biosciences	80	173.53 million	162.09 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

BCAX, COGT, XENE, and PTCT Headlines

Recent News About These Companies

73,728 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Legal & General Group Plc

September 5 at 3:36 AM | marketbeat.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4 at 5:30 PM | insidermonkey.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4 at 3:42 PM | finance.yahoo.com

The Manufacturers Life Insurance Company Invests $1.75 Million in Xenon Pharmaceuticals Inc. $XENE

September 4 at 4:31 AM | marketbeat.com

Corient Private Wealth LP Invests $1.73 Million in Xenon Pharmaceuticals Inc. $XENE

September 4 at 3:43 AM | marketbeat.com

Xenon to Present at Wells Fargo Healthcare Conference

September 3 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 10th Largest Position

September 3 at 4:23 AM | marketbeat.com

Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 2 at 5:22 AM | insidertrades.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Wellington Management Group LLP

September 2 at 4:56 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 1, 2026 | marketbeat.com

Headlands Technologies LLC Buys 23,074 Shares of Xenon Pharmaceuticals Inc. $XENE

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Has $42.11 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Buys Shares of 421,518 Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Stake in Xenon Pharmaceuticals Inc. $XENE

August 30, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $9.14 Million in Xenon Pharmaceuticals Inc. $XENE

August 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | globenewswire.com

What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders

August 28, 2026 | finance.yahoo.com

51,345 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Palo Alto Investors LP

August 28, 2026 | marketbeat.com

Man Group plc Acquires New Stake in Xenon Pharmaceuticals Inc. $XENE

August 28, 2026 | marketbeat.com

Cibc World Market Inc. Takes $1.21 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, COGT, XENE, and PTCT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$23.17 -0.17 (-0.73%)

As of 09/4/2026 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Cogent Biosciences NASDAQ:COGT

$34.76 -0.19 (-0.54%)

As of 09/4/2026 04:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$69.30 -2.10 (-2.94%)

As of 09/4/2026 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Xenon Pharmaceuticals NASDAQ:XENE

$59.75 -0.65 (-1.08%)

As of 09/4/2026 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, COGT, XENE, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, COGT, XENE, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, COGT, XENE, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, COGT, XENE, and PTCT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Cogent Biosciences NASDAQ:COGT

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, COGT, XENE, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, COGT, XENE, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, COGT, XENE, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, COGT, XENE, and PTCT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Cogent Biosciences NASDAQ:COGT

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools